Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose...
WATERTOWN, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,...
– Femasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA – – Femasys is committed...
NME is a progressive, typically fatal autoimmune disease characterized by brain inflammation, that has no disease-modifying treatment options availableSAN DIEGO...
Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on...
Toronto, Ontario--(Newsfile Corp. - October 3, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company") is pleased to announce the...
9th Circuit Court of Appeals Orders DEA to Respond to MMJ's Writ of Mandamus Within 30 DaysWASHINGTON D.C. / ACCESSWIRE...
PARSORTIX SYSTEM OUTPERFORMS CURRENT LABORATORY STANDARD FOR DISSEMINATED TUMOUR CELL HARVEST DTCs linked to cancer relapse even after prolonged remissionDTCs...
Provides framework for improving quality and equity of digital technology-enabled care modelsWASHINGTON, DC / ACCESSWIRE / October 2, 2023 /...
Based on pioneering research from Mayo Clinic, ECG-AI LEF aims to aid physicians in identifying low ejection fraction in patients...
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected...
- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early...
DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming...
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa...
Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CESTPARIS and CAMBRIDGE, Mass., Sept. 29, 2023...
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a...
Combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early...
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two...
DENVER, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions...